Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus.

作者信息

Koulouris Spyridon, Symeonides Phivos, Triantafyllou Konstantinos, Ioannidis Georgios, Karabinos Ilias, Katostaras Theofanis, El-Ali Mahmud, Theodoridis Theodoros, Vratsista Ekaterini, Thalassinos Nikolaos, Kokkinou Vassiliki, Nanas Ioannis, Stamatelopoulos Stamatios, Toutouzas Pavlos

机构信息

First Cardiology Department, Department of Endocrinology, Diabetes and Metabolism and Hematology Laboratory, Evangelismos Hospital, Athens, Greece.

出版信息

Am J Cardiol. 2005 Jun 1;95(11):1386-8. doi: 10.1016/j.amjcard.2005.01.092.

The effect of ramipril (an angiotensin [AT]-converting enzyme inhibitor), telmisartan (an AT-II type 1 receptor blocker), or their combination on inflammation and lipid peroxidation was assessed in 37 patients with type 2 diabetes who were free of coronary artery disease. All regimens were associated with a significant reduction of C-reactive protein and oxidized low-density lipoprotein cholesterol serum levels (p <0.001). These results further enlighten the mechanisms underlying the cardiovascular beneficial effect of renin-AT system inhibition.